{"name":"Adagene","slug":"adagene","ticker":"ADAG","exchange":"NASDAQ","domain":"adagene.com","description":"Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to trea","hq":"Suzhou, China","founded":0,"employees":"128","ceo":"","sector":"Antibody Engineering","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":3.65,"stockChange":-0.05,"stockChangePercent":-1.35,"marketCap":"$241M","metrics":{"revenue":7670902,"revenueGrowth":7332.8,"grossMargin":100,"rdSpend":0,"netIncome":-17609412,"cash":75844096,"dividendYield":0,"peRatio":-7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ADG126 Mono","genericName":"ADG126 Mono","slug":"adg126-mono","indication":"Other","status":"phase_1"},{"name":"ADG126-anti PD1","genericName":"ADG126-anti PD1","slug":"adg126-anti-pd1","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADG126 Mono","genericName":"ADG126 Mono","slug":"adg126-mono","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ADG126-anti PD1","genericName":"ADG126-anti PD1","slug":"adg126-anti-pd1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":7670902,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":7670902},{"period":"2024-12-31","value":103204},{"period":"2023-12-31","value":18111491},{"period":"2022-12-31","value":9292724}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":22033573,"rdSpendHistory":[{"period":"2025-12-31","value":22033573},{"period":"2024-12-31","value":28781412},{"period":"2023-12-31","value":36639146},{"period":"2022-12-31","value":81339540}],"sgaSpend":7075624,"operatingIncome":-21438295,"operatingIncomeHistory":[{"period":"2025-12-31","value":-21438295},{"period":"2024-12-31","value":-35951543},{"period":"2023-12-31","value":-23719866},{"period":"2022-12-31","value":-83920683}],"netIncome":-17609413,"netIncomeHistory":[{"period":"2025-12-31","value":-17609413},{"period":"2024-12-31","value":-33424111},{"period":"2023-12-31","value":-18946370},{"period":"2022-12-31","value":-79971847}],"eps":-0.7375,"epsHistory":[{"period":"2024-12-31","value":-0.7375},{"period":"2023-12-31","value":-0.4375},{"period":"2022-12-31","value":-1.85},{"period":"2021-12-31","value":-1.825}],"cash":74523782,"cashHistory":[{"period":"2025-12-31","value":74523782},{"period":"2024-12-31","value":85194502},{"period":"2023-12-31","value":109934257},{"period":"2022-12-31","value":143758678}],"totalAssets":78263297,"totalLiabilities":42913750,"totalDebt":6263222,"equity":35349547,"operatingCashflow":-15657450,"operatingCashflowHistory":[{"period":"2025-12-31","value":-15657450},{"period":"2024-12-31","value":-29700985},{"period":"2023-12-31","value":-28454839},{"period":"2022-12-31","value":-48611687}],"capex":-17053,"capexHistory":[{"period":"2025-12-31","value":-17053},{"period":"2024-12-31","value":-33580},{"period":"2023-12-31","value":-85012},{"period":"2022-12-31","value":-690938}],"freeCashflow":-15674503,"dividendsPaid":null,"buybacks":0,"employees":128,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.65,"previousClose":3.7,"fiftyTwoWeekHigh":4.75,"fiftyTwoWeekLow":1.3,"fiftyTwoWeekRange":"1.3 - 4.75","fiftyDayAverage":3.74,"twoHundredDayAverage":2.52,"beta":0.57,"enterpriseValue":166224624,"forwardPE":-7,"priceToBook":4.9,"priceToSales":31.47,"enterpriseToRevenue":21.67,"enterpriseToEbitda":-7.92,"pegRatio":0,"ebitda":-20999432,"ebitdaMargin":-273.8,"freeCashflow":-10250600,"operatingCashflow":-15657450,"totalDebt":6263222,"debtToEquity":12.1,"currentRatio":3.07,"returnOnAssets":-16,"returnOnEquity":-34.4,"analystRating":"","recommendationKey":"none","numberOfAnalysts":5,"targetMeanPrice":9.4,"targetHighPrice":14,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":21.2,"institutionHeldPercent":20.8,"sharesOutstanding":66072594,"floatShares":41416178,"sharesShort":668771,"shortRatio":1.95,"shortPercentOfFloat":1,"epsTrailing":-0.38,"epsForward":-0.52,"revenuePerShare":0.16,"bookValue":0.75,"officers":[{"age":59,"name":"Dr. Peter P.  Luo Ph.D.","title":"Co- Founder, Chairman, CEO and President of R&D"},{"age":48,"name":"Mr. Man Kin  Tam M.B.A.","title":"CFO & Director"},{"age":null,"name":"Ms. Ling  Zhou","title":"Executive Director & Head of Human Resources"},{"age":64,"name":"Dr. Qinghai  Zhao Ph.D.","title":"Chief Manufacturing Officer"},{"age":null,"name":"Mr. Mickael  Chane-Du","title":"Chief Strategy Officer"},{"age":null,"name":"Ms. Chunfang  Gu","title":"Executive Director of Finance"},{"age":50,"name":"Ms. Yan  Li M.B.A.","title":"Senior Vice President of Bioinformatics & Information Technology"},{"age":58,"name":"Ms. Xiaohong  She","title":"Senior VP & Head of Clinical Operations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.adagene.com","phone":"86 512 8777 3632"}}